

S 425

Budgeting for Opioid Addiction Treatment Act

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 7, 2019

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Feb 7, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/425>

Sponsor

Name: Sen. Manchin, Joe, III [D-WV]

Party: Independent • **State:** WV • **Chamber:** Senate

Cosponsors (9 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Feb 7, 2019
Sen. Blumenthal, Richard [D-CT]	D · CT		Feb 7, 2019
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Feb 7, 2019
Sen. King, Angus S., Jr. [I-ME]	I · ME		Feb 7, 2019
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 7, 2019
Sen. Shaheen, Jeanne [D-NH]	D · NH		Feb 7, 2019
Sen. Smith, Tina [D-MN]	D · MN		Feb 7, 2019
Sen. Warren, Elizabeth [D-MA]	D · MA		Feb 7, 2019
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Feb 7, 2019

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Feb 7, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 4793	Identical bill	Oct 23, 2019: Referred to the Subcommittee on Health.

Budgeting for Opioid Addiction Treatment Act

This bill imposes a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort.

The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee.

Any increase in federal revenues from the fee after rebates and discounts are subtracted must be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities.

HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.

Actions Timeline

- **Feb 7, 2019:** Introduced in Senate
- **Feb 7, 2019:** Read twice and referred to the Committee on Finance.